ROCHE HOLDING LTD S/ADR (RHHBY) analyst actions
Rating and price-target actions on RHHBY in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the RHHBY overview →
4 measured RHHBY analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Genentech Announces Positive Phase II Results for Dual GLP-1/GIP Receptor Agonist Enicepatide in People Living With Type 2 Diabetes and Overweight or Obesity | Press release | -0.29% | +1.22% | |
| Genentech Announces Positive Phase II Results for Petrelintide, an Amylin Analog Developed for People Living With Overweight and Obesity | Press release | -0.43% | -3.51% | |
| Genentech’s Susvimo Maintains Vision Over Five Years With Two Refills Per Year in People With Wet Age-Related Macular Degeneration (AMD) | Press release | +0.05% | +1.12% | |
| Genentech’s Fenebrutinib Maintains Near-Complete Suppression of Disease Activity and Disability Progression for up to Two Years in People With Relapsing Multiple Sclerosis | Press release | -0.40% | +0.37% |
Keep exploring
More RHHBY: earnings → · SEC filings → · RHHBY overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Glaukos Corporation (GKOS) | 452 | +0.04% | 51% |
| Cosmos Health Inc. (COSM) | 450 | 0.00% | 50% |
| CareDx, Inc. (CDNA) | 443 | -0.11% | 47% |
| Arvinas, Inc. (ARVN) | 442 | -0.26% | 42% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.